Rolling submission began last summer

Placing of shares comes ahead of submission to regulators for approval of drug for rare condition

Results are a record for Dublin-based company, which has recently listed on Nasdaq

Swixx BioPharma will sell cholesterol drug across central and eastern Europe

Irish specialist in rare diseases says successful drug could tap $1bn market

Sectors include health and safety, pharma, crop protection and refrigeration

Warrants were issued in September as part of the company’s acquisition of Aegerion

Chief executive Joe Wiley also received more than 6m share options in company

Company recently signed distribution agreement with Swixx BioPharma

Rare disease specialist says integration with newly acquired Aegerion completed ahead of time

Company said the impact of Covid-19 on its business has been minimised so far

Dublin-based biopharma company has cash position of $60.9m

New targets set for inclusion of women on leadership teams and in private companies

Firm acquired US-based Aegerion Pharmaceuticals earlier this year

Company has issued €1.1m in loan notes to fund specialisation in orphan diseases

Markets also rattled by growing unrest in France and fresh China-US trade concerns

Company that received the most funding was biopharmaceutical group Amryt Pharma

Elaine Sullivan leads cancer research firm to an EY Entrepreneur of the Year Award

European markets buoyed by speculation that US could resume trade talks with China

Amyrt’s EB development asset progressing through phase three clinical trial